Category Archives: Nano Medicine

NEW YORK, Oct. 16, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212)682-3025(888) 593-4771[emailprotected]

Conyers Park II Acquisition Corp. (NASDAQ: CPAA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Conyers Park II Acquisition Corp. (NASDAQ: CPAA)in connection with the company's proposed merger with Advantage Solutions Inc. ("Advantage Solutions"), a privately-held sales and marketing company. Under the terms of the merger agreement, CPAA will acquire Advantage Solutions through a reverse merger that will result in Advantage Solutions becoming a public company listed company. The proposed transaction implies an initial enterprise value for Advantage Solutions of approximately $5.2 billion. If you own CPAA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/conyers-park-ii-acquisition-corp/

Tottenham Acquisition I Limited (NASDAQ: TOTA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Tottenham Acquisition I Limited (NASDAQ: TOTA, TOTAU, TOTAW, TOTAR)in connection with the company's proposed merger with privately-held clinical-stage biopharmaceutical company, Clene Nanomedicine, Inc. ("Clene"). Under the terms of the merger agreement, Tottenham will acquire Clene through a reverse merger that will result in Clene becoming a public company listed on the Nasdaq Capital Market. The proposed transaction values Clene at $542.5 million, and the new entity will receive $25 million from Tottenham's trust account. If you own TOTA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/tottenham-acquisition-i-limited/

LF Capital Acquisition Corp. (NASDAQ: LFAC)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of LF Capital Acquisition Corp. (NASDAQ: LFAC)in connection with the proposed acquisition of Landsea Homes Incorporated ("Landsea Homes"). Under the terms of the acquisition agreement, LFAC will acquire Landsea Homes through a reverse merger that will result in Landsea Homes becoming a publicly-listed company. The combined company is expected to have a pro forma equity value of approximately $510 million. Upon closing, Landsea Homes' founder, Landsea Green Properties Co., Ltd., will own 67.4% of the combined company. If you own LFAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/news/lf-capital-acquisition-corp/

SOURCE WeissLaw LLP

https://weisslawllp.com

Read more:
WeissLaw LLP Reminds CPAA, TOTA, and LFAC Shareholders About Its Ongoing Investigations - PRNewswire

LOS GATOS, Calif.--(BUSINESS WIRE)--Advanced NanoTherapies, Inc., a privately-held medical device company committed to exploring nanotechnology for enhanced drug uptake and sustained retention, today announced it has closed on the final tranche of its seed-round financing for a total of $5.3 million as a result of achieving a successful pre-clinical milestone. Funding came from a variety of angel investment sources in the US, Canada, Europe, Asia, and the Middle East, including venture funding from Cleveland Clinic and ForMed Ventures of Taiwan.

Advanced NanoTherapies is led by CEO Marwan Berrada-Sounni, an entrepreneur with extensive experience in percutaneous therapies, including electrophysiology, structural heart, and cardiovascular and endovascular devices.

Our initial focus is on bringing a safer and more effective therapeutic option to patients with peripheral artery disease (PAD) using Sirolimus-coated angioplasty balloons, said Berrada-Sounni. This funding will help us accelerate the development process, build our infrastructure, and move towards bringing this novel technology to patients with PAD.

Advanced NanoTherapies technology platform leverages patented biodegradable functionalized nanoparticles (f-NPs) and a proprietary coating process developed at Cleveland Clinic.

We know that f-NPs enable and improve drug uptake and retention into cells and tissue, said inventor Vinod Labhasetwar, PhD., Professor and Endowed Chair of Nanomedicine, Department of Biomedical Engineering at Cleveland Clinic Lerner Research Institute. Due to technically challenging requirements involved in delivering Sirolimus efficiently to a stenosed artery, Advanced NanoTherapies use of f-NP is an innovative approach.

Advanced NanoTherapies licensed the technology from Cleveland Clinic Innovations.

While drug delivery using coated balloons is a well-established treatment strategy, our vision for using f-NP technology to address PAD represents a major advancement in drug-coated balloon (DCB) technology, said Dr. Mehdi Shishehbor, President, Harrington Heart and Vascular Institute University Hospitals, Cleveland and co-founder and Chief Medical Officer of Advanced NanoTherapies. This technology has implications for many other applications, such as coronary and peripheral in-stent restenosis, below-the-knee tibial disease in CLI, and dialysis AV graft treatment.

Berrada-Sounni added that the company will be working closely with the FDA to achieve an early feasibility study and introduce its technology to human populations.

About Advanced NanoTherapies

Co-founded by Marwan Berrada-Sounni, Advanced NanoTherapies, Inc. is a highly specialized medical device company that is developing a nanoparticle technology-based platform for drug delivery. The company is currently focused on cardiovascular and endovascular applications to bring a safer therapeutic option to patients with PAD using Sirolimus-coated angioplasty balloons. To learn more about Advanced NanoTherapies, visit http://www.AdvNanoT.com.

Go here to read the rest:
Advanced NanoTherapies Raises $5.3 Million in Seed-Round Financing - Business Wire

Business Internet Service Market 2020: Industry Size & Share, Business Strategies, Growth Analysis, Regional Demand By 2025 By Market Study Report

The report published on Business Internet Service Market is an invaluable foundation of insightful data helpful for the decision-makers to form the business strategies related to R&D investment, sales and growth, key trends, technological advan...

The Logistic Software report provides independent information about the Logistic Software industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challeng...

The research study 360 Degree Feedback Software market 2020 provides the detailed analysis of the current market status, investment plans, production and consumption, price trends, and analysis by market player, by region, by type, by application e...

The research study APP Store Monetisation market 2020 provides the detailed analysis of the current market status, investment plans, production and consumption, price trends, and analysis by market player, by region, by type, by application etc, an...

The Pumps and Motors report provides independent information about the Pumps and Motors industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges...

Go here to see the original:
Nanorobots Market 2020: Applications, Types and Growing Trends in Market, Gross - News by aeresearch

In September 2020, the healthcare industry reported 84 deals worth $28.2 billion as compared to the last 12-month average (September 2019 to August 2020) of 75 deals worth $11.6 billion.

Deal value in the M&A market decreased in September 2020 compared to $35.7 billion in August 2020. Gilead Sciences to acquire Immunomedics, for $88.0 per share in cash, valuing the company at approximately $21 billion contributing 74 per cent of the total deal value during September 2020.

Other notable deals in the month are: Permira, a private equity firm to acquire Neuraxpharm Arzneimittel GmbH, a pharma company focused on the treatment of central nervous system disorders, for $1.8 billion; and Mylan N.V. to acquire the Intellectual Property and Commercialisation Rights of Aspen Pharmacare Holdings Limiteds Thrombosis Business in Europe, for $759 million.

Deal activity in pharma industry in September 2020

VC investments reported a marginal increase in deal value in September 2020

The healthcare industry reported 117 venture capital (VC) deals worth $3.7 billion in September 2020, compared to the last 12-month average (September 2019 to August 2020) of 117 deals worth $2.4 billion.

XtalPi Inc, a computation-driven biotech startup raising $318.8 million in series C round of financing to further develop its ID4 platform, in an attempt to build an AI-powered digital drug R&D infrastructure; Recursion Pharmaceuticals, raising $239.0 million in an oversubscribed series D financing to support the clinical development of its therapeutic pipeline; and InventisBio, a clinical-stage biotech company raising $147 million in Series D financing to support its current products into phase II clinical studies in China and the US, including D-0502 trials in hormone receptor-positive breast cancer and D-0120 trials in gout are the major VC deals reported in September 2020.

Go here to read the rest:
Deal value in the M&A market decreased in Sept 2020 compared to $35.7 bn in Aug 2020 - Express Pharma

Testing new cancer drugs on 3D-printed tumor cells. Analyzing the gut microbiome to determine the best medicine for Crohns disease. Identifying genetic pairs so that a drug can turn off a cancer cell.

These are just a few of the overlaps of biology, physics, computer science, mathematics, engineering, materials science and nanotechnology that make up the new field of bio-convergence.

The Israel Innovation Authorityis betting on bio-convergence as the next big thing from the Startup Nation.

Israel to invest NIS 100 million in bio-convergence

The IIA announced in January that it would invest up to about $30 million in bio-convergence technologies and companies. In July, the governmental agency added a call for R&D proposals from academia and industry in the field of bio-convergence with a budget of $4 million.

In August, a third call for bio-convergence proposals this time for collaboration between Israeli and South Korean companies came with a $4.16 million budget and a plan to provide grants up to 50 percent of R&D expenses.

The bio-convergence push is a bit of a departure for the IIA.

We usually work in a bottom up approach and very seldom intervene and select a specific technological field for strategic investments, Anya Eldan, vice president of the IIAs Startup Division, tells ISRAEL21c. In the past it has been cyber and fintech. Now weve identified bio-convergence as the next growth engine for the Israeli economy.

Anya Eldan, vice president of the IsraelInnovation Authoritys Startup Division. Photo: courtesy

Developing disease-fighting drugs the old-fashioned way takes decades and billions of dollars. The new era of pharma will see researchers from multiple disciplines working together.

When we started to look for the next growth engine, we realized that none of the major pharmaceutical companies are invested in bio-convergence, Eldan explains. Theyre looking at biology but theyre not sure how to approach it.

Israel, however, is a small country where everyone knows one another, making it relatively easy to put together multidisciplinary teams.

On a folksier level, Eldan says Israelis large Friday night Shabbat dinners naturally foster collaboration. People have to find things to talk about. So, a doctor mentions at the dinner table he has a patient without a solution and the engineer in the family says, That shouldnt be, and from there a startup is born.

This trend could have a major impact on the global healthcare system crisis. Health expenditures worldwide were expected to reach $10 trillion by 2022even before the advent of Covid-19. Half the US population is considered chronically ill, accounting for some 85% of the total expenditure on healthcare services.

Unlocking academic research

The IIA has identified approximately 80 companies working in the field of bio-convergence. Much of the knowhow is tucked away in Israels academic centers.

Ronit Satchi Fainaro is a prime example.

Named Woman of the Year by the Israeli business publication Globes in 2019, Satchi Fainaro heads the 30-person cancer research and nano-medicine laboratory in the department of physiology and pharmacology at Tel Aviv University.

Satchi Fainaros lab includes research associates in biology, chemistry, medical engineering, bioinformatics and even an architecture student, she tells ISRAEL21c. We are living in the post-genomic era, so theres a lot of room for computer science.

Satchi Fainaros lab developed a method for 3D printing cancerous brain tumors using MRI on images.

We do the image analysis and convert it to a file that a 3D printer can read. Then we create a 3D-printed tumor its like a Mini-Me of that tumor, she says, referring to the Mike Meyers character from the Austin Powers films.

Satchi Fainaros lab creates not one but up to 20 mini-tumors, which are then connected to a set of tubes and pumps that deliver simulated blood and most importantly chemotherapy or other cancer treatments. That allows physicians to test drugs on a perfect copy of the actual tumor.

Satchi Fainaro is also working on an immunotherapy nano-vaccine for melanoma and an immune-modulated response against Covid-19.

Sequencing the microbiome

Jonathan Solomon and Assaf Oron are the CEO and chief business development officer, respectively, of BiomX, another Israeli bio-convergence pioneer.

BiomX is working on a treatment for Crohns and other inflammatory bowel diseases by sequencing the bacteria in a patients microbiome in order to deliver a gut-punch to the exact bacteria causing symptoms.

BiomXs technology is based on the hypothesis that these diseases are driven by the microbiome and that specific bacteria seem to be pro-inflammatory and antibiotic resistant, Solomon tells ISRAEL21.

Bacteriophage image courtesy of BiomX

Bio-convergence techniques assure that a patient receives the right phages a type of virus that infects bacteria to kill only the offending microbes.

Antibiotics are very indiscriminate killers, Solomon says, which leads to the killing of both harmful and beneficial bacteria and, in many cases, the development of antibiotic-resistant bacteria. Phages are very precise. There are no side effects.

Beyond IBD, acne and liver disease are next on BiomXs list. Even cancer is a possibility.

BiomXs technology was initially developed and licensed from the Weizmann Institute in Rehovot. The company has 100 employees and is publicly traded in the United States.

Synthetic lethality

Then theres Pangea, whose bio-convergence niche is synthetic lethality.

Its a very simple notion with a confusing name, CTO Tuvik Beker tells ISRAEL21c.

The basic idea is that genes often act in pairs. If a gene is acting unnaturally in a tumor (for example, it may be shut down due to mutation or abnormal expression), identifying and shutting down the genes partner can selectively kill the malignant cells.

Pangea brings the computational element.

If there are 20,000 genes in the human genome, simple math means there are about 400 million gene pairs, Beker explains. To test all these pairs for synthetic lethality is very challenging.

As a result, most companies restrict themselves to a couple of hundred genes that they know are important in cancer. Pangea, by contrast, looks for paired genes that are vulnerable to collateral damage, not just the ones driving the tumor, Beker says.

The Tel Aviv-based company hopes to launch its service commercially as early as 2021 with a focus on providing personalized treatment recommendations.

Read the rest here:
What's the next big thing from Israel? Bio-convergence - ISRAEL21c

Global Nanotechnology Drug Delivery Market was valued US$ XX Bn in 2018 and is expected to reach US$ 98.2 Bn by 2026, at a XX% CAGR of around during a forecast period.

Various novel technologies for developing effective drug delivery systems came into existence among which nanotechnology platforms for achieving targeted drug delivery are gaining prominence nowadays. Research in the medical field includes the development of drug nanoparticles, polymeric and inorganic biodegradable nano-carriers for drug delivery, and surface engineering of carrier molecules.

The report contains a detailed list of factors that will drive and restrain the growth of the Nanotechnology Drug Delivery Market. Such as, rapidly expanding areas of research and development to develop novel nano-medicine are expected to drive the nanotechnology drug delivery market growth in the future. Additionally, one of the major factors assisting market growth is the growing prevalence of infectious diseases and cancer, developing nanotechnology research, and increasing demand for novel drug delivery systems. However, high cost coupled with stringent regulatory scenario hinders the market growth to some extent.

Nanoparticles are expected to account for the largest XX% market share by 2026. The segment dominated the market as key nanoparticles like gold nanoparticles, dendrimers, and fullerenes are used in pharmaceutical drug delivery.The report offers a brief analysis of the major regions in the global nanotechnology drug delivery market, namely, APAC, Europe, North America, South America, and the Middle East & Africa. North America dominated the nanotechnology drug delivery market in 2018, because of high medical reimbursement facilities, and technological advancement. The APAC is projected to have the fastest growth, owing to a rapidly increasing population, an increase in consumer awareness, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing economies such as China, and India in this region.

Nanotechnology drug delivery market report gives a competitive analysis of the individual standing of the companies against the global landscape of the medical industry. The forecast also provides the estimated trends in demand for the global market and their impact on the sizes of these companies to help the reader curate profitable business strategies. Such as Pfizer, Inc., AstraZeneca and Amgen signed agreements to collaborate with BIND Therapeutics to develop nano-medicines. These initiatives are expected to fuel the growth of the nanotechnology drug delivery market in the upcoming future.

Global Nanotechnology Drug Delivery Market Request For View Sample Report Page :@https://www.maximizemarketresearch.com/request-sample/39035

The objective of the report is to present comprehensive analysis of Global Nanotechnology Drug Delivery Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Nanotechnology Drug Delivery Market dynamics, structure by analyzing the market segments, and project the Global Nanotechnology Drug Delivery Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Nanotechnology Drug Delivery Market make the report investors guide.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.Scope of the Global Nanotechnology Drug Delivery Market

Global Nanotechnology Drug Delivery Market, by Technology

Nanocrystals Nanoparticleso Dendrimerso Gold Nanoparticleso Dendrimerso Fullereneso Others Liposomes Micelles Nanotubes OthersGlobal Nanotechnology Drug Delivery Market, by Application

Neurology Oncology Cardiovascular/Physiology Anti-inflammatory/Immunology Anti-infective OthersGlobal Nanotechnology Drug Delivery Market, by Region

North America Asia Pacific Europe Middle East & Africa South AmericaKey players operating in the Global Nanotechnology Drug Delivery Market

Johnson & Johnson Merck & Co Roche Bayer Novartis Pharmaceuticals Pfizer AstraZeneca Amgen Celgene Corporation Angiotech Pharmaceuticals Capsulution Pharma AlphaRx Inc. Calando Pharmaceuticals Copernicus Therapeutics Elan Corporation Nanotherapeutics PAR Pharmaceutica Taiwan Liposome Co. AbbVie, Inc Amgen, Inc

Global Nanotechnology Drug Delivery Market Do Inquiry Before Purchasing Report Here @ :https://www.maximizemarketresearch.com/inquiry-before-buying/39035

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email: sales@maximizemarketresearch.comContact: +919607065656 / +919607195908Website:www.maximizemarketresearch.com

Read more:
Global Nanotechnology Drug Delivery Market : Industry Analysis and Forecast (2019-2026): By Technology, Application and Region. - re:Jerusalem